Switzerland is narrowing the gap with other European countries when it comes to the cost of medicines. But generics are still double the price and harder to find in the Alpine nation.
This content was published on
2 minutes
Keystone-SDA/jdp
The 11th annual analysisExternal link by the industry association Interpharma and the umbrella group of health insurers santésuisse found that patent-protected drugs were on average 4.5% cheaper in the nine reference countries than in Switzerland. This is an improvement from the price difference of 7% last year. Original products that have expired are 10% less abroad.
The price gap remains the largest for generics. In Switzerland, generics are 42% more expensive – a slight decrease from the previous year (48%). They are also less common. According to data from the Organisation for Economic Cooperation and Development (OECD), the share of generics in Switzerland is 27%, compared to 83% in Germany.
The price reductions have helped save CHF1 billion ($1.09 billion) since 2012 according to Interpharma. Medicines account for around 12% of total healthcare costs in Switzerland.
“Insurance premium payers are still spending around CHF200 million more than in the comparison countries, including for patented medicines. The savings could be even greater for generics,” said Verena Nold, director of santésuisse.
The analysis attributes the lower prices to regular price reviews by Swiss public health authorities as well as evolution in exchange rates.
Interpharma also points out that it is taking longer for new, innovative products to be included on the list for health insurance reimbursement. Last year, only 24% of the products that applied for reimbursement were added to the drug specialties listExternal link within 60 days. The number of applications that were not included for reimbursement reached a new high in 2019 with 136 products.
The nine European countries included in the comparison are Germany, Austria, Belgium, Denmark, Finland, France, Great Britain, the Netherlands and Sweden.
Popular Stories
More
Swiss Abroad
The citizenship obstacle course facing spouses of Swiss Abroad
This content was published on
The Ethos Foundation recommends that shareholders vote against all compensation-related items at the Annual General Meeting on March 7.
Top Swiss firms close to reaching gender quota in boards
This content was published on
The proportion of women on the boards of directors of the fifty largest listed companies in Switzerland currently stands at 28%.
Swiss committee wants to end government resignations during legislative term
This content was published on
Members of the Federal Council should no longer be able to leave office before the end of their term, according to a House of Representatives committee.
Swiss government seat: Ritter and Pfister nominated to succeed Amherd
This content was published on
Markus Ritter from St Gallen and Martin Pfister from Zug were officially nominated by the Centre Party on Friday to succeed Defence Minister Viola Amherd.
Top Swiss court rejects Russian request for administrative tax assistance
This content was published on
There is currently no reason to transmit banking information to the Russian Federation, the Swiss Federal Court has ruled.
After strike by radiologists, doctors demonstrate in Bern
This content was published on
Following a strike by radiology technicians in Fribourg, doctors, vets, dentists and chiropractors expressed their frustration on Friday outside parliament in the Swiss capital.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Generic drugs remain twice as expensive in Switzerland
This content was published on
Drug prices in Switzerland remain higher than in other major European markets, especially when it comes to generic drugs, which are twice as expensive in Switzerland as elsewhere.
This content was published on
Curing cancer for the masses could be challenging if healthcare systems are crippled by rapidly rising cancer drug prices.
This content was published on
Switzerland could save millions of francs by prescribing low-priced biotech drug copies, known as biosimilars, instead of expensive biologicals.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.